Contribute Try STAT+ Today

Months and even years after a successful bone marrow transplant, when patients in remission finally start to see their cancer nightmare fading away, the cure can turn against them.

Immune cells from the transplant donor view the patient’s body as foreign and start attacking tissues and organs. The cancer is gone, but now patients must deal with painful mouth sores, eyes that cannot produce tears, skin rashes, immobile joints and damaged organs. The debilitating condition is called chronic graft-versus-host disease, or GVHD, and can affect as many as half of bone marrow transplant patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.